Lilly completes acquisition of immuno-oncology firm Armo BioSciences
Strategic Expansion in Cancer Treatment: Eli Lilly and Company (Lilly), a leading US pharmaceutical firm, has finalized its acquisition of Armo BioSciences, a California-based immuno-oncology company, for $1.6 billion. This move is part of Lilly’s strategic initiative to enhance its immuno-oncology program, one of the most promising areas in cancer research today. Details of the […]